Use of SV40 Vectors to Treat Chronic Myeloid Leukemia (CML)

Plain-language summary

This study examined the use of SV40 vectors carrying siRNA in patients diagnosed with chronic myeloid leukaemia (CML). The approach uses a viral vector to deliver small interfering RNA in order to silence the disease-driving gene product. Adults aged 18 and over with CML took part, and the study has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

Hadassah Medical Organization

Intervention

SV40 vectors carrying siRNA

Start date

9/1/2005

Estimated completion

11/1/2007

Countries

Israel

Related genes

Locations

• Jerusalem, Israel

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Diagnosis of CML

Exclusion Criteria:

* Under 18 years old
* Pregnant